Weekly Roundup: Enrolment completed and conference top tips and takeaways
Gesynta Pharma completes enrolment in Phase 2 NOVA trial evaluating vipoglanstat in endometriosis
Gesynta Pharma AB, a clinical-stage biotech company developing vipoglanstat, a non-hormonal, non-opioid therapy that could transform the standard of care for women with endometriosis, announced that it has completed enrolment in NOVA, its Phase 2 clinical proof-of-concept and dose-finding trial. A total of 213 patients were randomized, exceeding the original target of 190, with full enrolment achieved more than three months ahead of schedule. Topline data from the trial is anticipated in Q2 2027
Mestag Therapeutics appointed Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors
Mestag Therapeutics, a clinical-stage biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease and cancer, announced the appointments of Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors. These appointments strengthen the Board as Mestag evaluates MST-0312 in the Phase 1 STARLYS trial, currently enrolling patients with advanced solid tumours.
Hansa Biopharma announced submission of IND Application to US FDA for HNSA-5487 in GBS, and presentation of late-breaking abstract at ASN Kidney Week
Hansa Biopharma AB, announced that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for HNSA-5487, Hansa’s novel IgG-cleaving enzyme, to support clinical development in Guillain-Barré syndrome (GBS).
The Company also announced that the European Post-Authorization Efficacy and Safety (PAES) study of Idefirix® (imlifidase) has been selected by the Committee for an oral abstract presentation in the High-Impact Clinical Trials session at ASN Kidney Week in Denver, US.
New long-term and real-world data on presented at the 10th Joint ACTRIMS-ECTRIMS Meeting 2026
Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announced the presentation of new scientific data at the 10th Joint ACTRIMS-ECTRIMS Meeting, held October 21-23, 2026, in Toronto, Canada.
🎥 Optimum TV
If you weren’t able to join us, or simply want to revisit some of the most insightful discussions from the day, you can now watch the Top Takeaways from the first six panel sessions on Optimum TV: Optimum Strategic Communications – YouTube
Whether you attended the event or missed it entirely, these short video round-ups are a great way to catch up on the conversations and perspectives that resonated most with delegates.
Stay tuned for the investor panel snippet; we will be posting next week.
The response has been overwhelmingly positive with many saying it was the best Optimum Conference yet! We’d love your feedback – what would you like to see at Optimum’s 19th Annual Healthcare Investor Conference on October 7th 2027?
🔗👉 PARTICIPATE IN THE FEEDBACK SURVEY
🔗👉 VIEW THE CONFERENCE PHOTO GALLERY
👥Industry events
BIO-Europe 2026 – Cologne, Germany | 9–11th Nov 2026
Connecting with the global biotech community – Our CEO, Mary Clark, and Associate Director, Zoe Bolt, will be attending BIO-Europe 2026, one of the leading international dealmaking events for the life sciences industry.
The team are looking forward to meeting with companies, investors and potential partners to discuss collaboration opportunities. Get in touch to schedule a get-together.
Don’t miss Mary’s panel at 9:00 CET entitled – Pitch, Present, Persuade: Become a Powerful Corporate Communicator.
Jefferies Global Healthcare Conference & London Life Sciences Week
London | 15-20 November 2026
The Official Networking Event Guide, produced by Optimum Strategic Communications and Catalyst Advisors LP in partnership with Jefferies, is now live!
The guide brings together the key receptions, workshops, panel discussions, networking events and industry gatherings taking place throughout the week, helping attendees make the most of their time in London.
🔗👉 VIEW THE OFFICIAL NETWORKING EVENT GUIDE
Don’t miss your chance to discover what’s happening across one of the busiest weeks in the life sciences calendar and start planning your schedule today.
5K London Landmarks Run | 17 November 2026
Join us ahead of a busy week of meetings and events during London Life Sciences Week and the Jefferies Global Healthcare Conference. Optimum Strategic Communications and Catalyst Advisors LP will welcome life sciences professionals for an early morning run through some of London’s most iconic landmarks. 👉Sign up here
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
